Intellia Therapeutics Finalizes Terms for $400M At-The-Market Offering
NTLA has more than doubled off its 52-week low of $5.9 on elevated volume (3.1× avg).
Summary
Intellia Therapeutics filed a prospectus supplement detailing the terms of its expanded $400 million At-The-Market (ATM) offering, enabling the company to sell common stock to fund operations and clinical development.
Key Events · Financing and Capital Events · NTLA
-
Formalizes $400M ATM Offering
Intellia Therapeutics filed a 424B5 prospectus supplement to finalize the terms of its expanded At-The-Market (ATM) equity offering, allowing the sale of up to $400 million in common stock.
-
Significant Potential Dilution
The offering, if fully utilized at an assumed price of $14.28 per share, could result in the issuance of approximately 28.01 million new shares, representing a potential dilution of about 24.08% to existing shareholders.
-
Capital for Clinical Development
Proceeds from the offering are intended to fund research and clinical development of pipeline candidates, including the recently cleared MAGNITUDE Phase 3 trial, working capital, and general corporate purposes, extending the company's liquidity.
-
Follows Concurrent 8-K Announcement
This filing provides the detailed prospectus for the ATM program expansion, which was announced in a separate 8-K filing on the same date, March 2, 2026.
Analysis · NTLA · Life Sciences
This 424B5 prospectus supplement formalizes the terms of Intellia Therapeutics' expanded At-The-Market (ATM) equity offering, allowing the company to sell up to $400 million in common stock. This filing provides the detailed legal framework for the ATM program, which was announced in a separate 8-K filing on the same day, March 2, 2026. The offering, if fully utilized at an assumed price of $14.28 per share, could result in the issuance of approximately 28.01 million new shares, representing a potential dilution of about 24.08% to existing shareholders. While dilutive, this substantial capital raise is crucial for funding ongoing research and clinical development, including the recently cleared MAGNITUDE Phase 3 trial, and extends the company's liquidity runway. Investors should monitor the pace of ATM sales and their impact on share price.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1944 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTLA was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $5.90 to $28.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.